Onconetix, Inc. (ONCO): Cost of Revenue

Annual figures by period end, from SEC filings.

$182.5K

Year ended 2025-12-31

$126.6K

Trailing 12 months to 2026-06-30

2023-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$182.5K	-87.6%	2026-03-13, From 2025-01-01
2024-12-31	$1.47M	+23.9%	2026-03-13, From 2024-01-01
2023-12-31	$1.19M	n/a	2025-06-02, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Onconetix, Inc. (ONCO)	2025-12-31	$182.5K	-87.6%
Lexaria Bioscience Corp. (LEXX)	2025-08-31	$2.7K	-43.6%
60 Degrees Pharmaceuticals, Inc. (SXTP)	2025-12-31	$781.7K	+103.2%
Polomar Health Services, Inc. (PMHS)	2025-12-31	$188.1K	+573.8%
Dare Bioscience, Inc. (DARE)	2025-12-31	$295.8K	n/a
BioXcel Therapeutics, Inc. (BTAIQ)	2025-12-31	$164.0K	-92.3%
Bespoke Extracts, Inc. (BSPK)	2024-12-31	$664.5K	+50.2%
PMGC Holdings Inc. (ELAB)	2025-12-31	$404.8K	n/a
China SXT Pharmaceuticals, Inc. (SXTC)	2026-03-31	$889.4K	-35.2%

Compare ONCO, LEXX, SXTP, PMHS side by side · Screen every company in Pharmaceutical Preparations ↗